Matthew Sorenson

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source: DePaul University

Matthew Sorenson, PhD, APN, ANP-C​​​, Director at School of Nursing, Associate Professor in Nursing, and a Consultant for the Myalgic Encephalomyelitis & Chronic Fatigue Syndrome Research Team at the Center for Community Research, College of Science and Health, DePaul University, Chicago, Illinois, US. His research interests include immunological changes in individuals with multiple sclerosis and chronic fatigue illnesses.[1][2]

Book chapter[edit | edit source]

Notable studies[edit | edit source]

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. https://csh.depaul.edu/faculty-staff/faculty-a-z/Pages/nursing/matthew-sorenson.aspx
  2. https://csh.depaul.edu/about/centers-and-institutes/ccr/myalgic-encephalomyelitis-cfs/Pages/default.aspx
  3. Jason, Leonard A; Sorenson, Matthew; Evans, Meredyth; Brown, Abigail; Flores, S; Sunnquist, Madison; Schafer, C (2013), "The implications of sensitization and kindling for chronic fatigue syndrome", N. Gotsiridze-Columbus (Ed.),Encephalitis, Encephalomyelitis, Encephalopathies: Symptoms, causes and potential complications (pages 73-94), New York: Nova Science 
  4. Jason, Leonard A.; Torres-Harding, Susan; Maher, Kevin; Reynolds, Nadia; Brown, Molly; Sorenson, Matthew; Donalek, Julie; Corradi, Karina; Fletcher, Mary Ann; Lu, Tony (2007), "Baseline Cortisol Levels Predict Treatment Outcomes in Chronic Fatigue Syndrome Nonpharmacologic Clinical Trial", Journal of Chronic Fatigue Syndrome, 14 (4): 39-59, doi:10.3109/10573320802092039 
  5. Torres-Harding, Susan; Sorenson, Matthew; Jason, Leonard; Maher, Kevin; Fletcher, Mary Ann (2008), "Evidence for T-helper 2 shift and association with illness parameters in chronic fatigue syndrome (CFS)", Bulletin of the IACFS/ME, 16 (3): 19–33., PMID 21234277 
  6. Jason, L.A., Porter, N., Herrington, J., & Sorenson, M., & Kubow, S. (2009). Kindling and oxidative stress as contributors to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Journal of Behavioral and Neuroscience Research, 7, 1-17. PMCID: PMC3022475
  7. Jason, Leonard; Sorenson, Matthew; Porter, Nicole; Brown, Molly; Lerch, Athena; Van der Eb, Constance; Mikovits, Judy (2010), "Possible Genetic Dysregulation in Pediatric CFS", Psychology, 1 (4): 247-251, doi:10.4236/psych.2010.14033 
  8. Porter, Nicole; Lerch, Athena; Jason, Leonard; Sorenson, Matthew; Fletcher, Mary Ann; Herrington, Joshua (2010), "A Comparison of Immune Functionality in Viral versus Non-Viral CFS Subtypes", Journal of Behavioral and Neuroscience Research, 8 (2): 1-8, PMID 24634898 
  9. Jason, L. A., Sorenson, M., Porter, N., & Belkairous, N. (2011). An Etiological Model for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Neuroscience and Medicine, 2(1), 14–27. http://doi.org/10.4236/nm.2011.21003
  10. Sorenson, Matthew; Jason, Leonard; Lerch, Athena; Porter, Nicole; Peterson, Jonna; Mathews, Herbert (2012). "The Production of Interleukin-8 is Increased in Plasma and Peripheral Blood Mononuclear Cells of Patients with Fatigue". Neuroscience and Medicine. 03 (01): 47–53. doi:10.4236/nm.2012.31007. ISSN 2158-2912. 
  11. Jason, L.A., Sorenson, M., Evans, M., Brown, A., Flores, S., Sunnquist, M., & Schafer, C. (2013). The implications of sensitization and kindling for chronic fatigue syndrome. In N. Gotsiridze-Columbus (Ed.),Encephalitis, Encephalomyelitis, Encephalopathies: Symptoms, causes and potential complications.(pp.73-94). New York: Nova Science
  12. Sorenson, M., Jason, L.A., Peterson, J., Herrington, J., & Mathews, H. (2014). Brain derived neurotrophic factor is decreased in Chronic Fatigue Syndrome and Multiple Sclerosis. Journal of Neurology & Neurophysiology, S12: S2-013.
  13. Kubow, Stan & Sorenson, Matthew & Alkazemi, Dalal & Jackson Roberts, Lyman & Naselli Adamski, Katherine & Jason, Leonard. (2015). Novel Associations of F2-Isoprostanes, F3- Isoprostanes and Isofurans in Older Adults with Chronic Fatigue Syndrome: An Exploratory Study. Clinical Research: Open Access. 1. 1-4. doi:10.16966/clroa.103
  14. Jason, LA; Ohanian, D; Brown, A; Sunnquist, M; McManimen, S; Klebek, L; Fox, P; Sorenson, M (2017), "Differentiating Multiple Sclerosis from Myalgic Encephalomyelitis and Chronic Fatigue Syndrome", Insights in Biomedicine, 2 (2), doi:10.21767/2572-5610.100011 
  15. Sorenson, Matthew; Furst, Jacob; Mathews, Herbert; Jason, Leonard A. (2017), "Dysregulation of cytokine pathways in chronic fatigue syndrome and multiple sclerosis", Fatigue: Biomedicine, Health & Behavior, 5 (3): 145-158, doi:10.1080/21641846.2017.1335237 

Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.